<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35254">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02041520</url>
  </required_header>
  <id_info>
    <org_study_id>R-2011-785-058</org_study_id>
    <nct_id>NCT02041520</nct_id>
  </id_info>
  <brief_title>Effect of Omega 3 Fatty Acids on Oxidative Stress in HIV Seropositive Patients</brief_title>
  <official_title>Effect of Omega 3 Fatty Acids on Oxidative Stress in Seropositive HIV Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coordinación de Investigación en Salud, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Mexicano del Seguro Social</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Coordinación de Investigación en Salud, Mexico</source>
  <oversight_info>
    <authority>Mexico: Federal Commission for Protection Against Health Risks</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction: Highly active antiretroviral therapy (HAART) has showed its effectiveness in
      the prevention of complications in seropositive for HIV patients. However, they develop some
      manifestations such as lipodystrophy, dyslipidemia, and glucose intolerance increasing
      cardiovascular risk.

      Clinical trials in general population and in patients on hemodialysis have demonstrated a
      significant reduction in cardiovascular events using fish oil. Omega-3 fatty acids are
      believed to be beneficial in prevention of atherosclerosis reducing lipids levels specially
      triglycerides.  Also in general populations it has been described a benefit effect of omega
      3 acids on oxidative stress.

      Objective: to know the effect of omega 3 acids on different markers of oxidative stress in
      seropositive HIV patients.

      Methods: We will perform a randomized parallel controlled clinical trial in seropositive HIV
      patients from 20 to 55 years old on clinical score A1, A2, B1 or B2 who received HAART. They
      will be randomly assigned to receive omega 3 fatty acids 2.4 g (Zonelabs, Marblehead MA) or
      placebo for 6 months. At baseline anthropometric measurements, lipid profile, glucose and
      stress oxidative levels (nitric oxide, malondialdehyde, total glutathion, and lipid
      peroxidation products) will be evaluated.

      Sample size was calculated according to different variables. We selected the biggest one
      calculated for a difference in nitric oxide of 25% after treatment between groups and a
      standard deviation (SD) value of 10µmol/L.  Whit this information we obtained a sample size
      of 31 patients per group for an 80% statistical power with α= 0.05.  Assuming a 15% patient
      lost, a sample size of 35 per group was considered.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Change on malondialdehyde after treatment with omega 3 acids for 6 months compared with placebo in HIV seropositive patients</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change on total glutathion after treatment with omega 3 acids for 6 months compared with placebo in HIV seropositive patients</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on nitric oxide after treatment with omega 3 acids for 6 months compared with placebo in HIV seropositive patients</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Change on viral load after treatment with omega 3 acids for 6 months compared with placebo in HIV seropositive patients</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>HIV/AIDS</condition>
  <arm_group>
    <arm_group_label>Omega 3 fatty acids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>omega 3 fatty acids, 2.4 g per day, requiring intake 2 capsules (600mg each one) in the morning  and two at night (Zonelabs, Marblehead MA) for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (olive oil gelcaps) in similar presentation as omega 3 fatty acids, requiring intake 2 capsules in the morning and two at night (Perfect Source, Fullerton CA, product code number PER 1016, lot number 8A0019/1600-1)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omega 3 fatty acids</intervention_name>
    <description>omega 3 fatty acids will be administered until progression or unacceptable toxicity develops during 6 months follow up.</description>
    <arm_group_label>Omega 3 fatty acids</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Zonelabs, Marblehead MA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Seropositive HIV patients from 20 to 55 years old

          -  On clinical score A1, A2, B1 or B2

          -  Patients who received highly active antiretroviral therapy for at least 3 months.

        Exclusion Criteria:

          -  Patients diagnosed with diabetes mellitus

          -  Patients diagnosed with hypertension

          -  Patients using hypolipidemic agents or diagnosed with dyslipidemia  before receiving
             HAART therapy.

          -  Patients using protease inhibitors
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norma Amador, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Mexicano del Seguro Social</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Norma Amador, PhD</last_name>
    <phone>+524777174800</phone>
    <phone_ext>31315</phone_ext>
    <email>norma.amador@imss.gob.mx</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Texar A Pereyra, MD</last_name>
    <phone>+524777174800</phone>
    <phone_ext>31742</phone_ext>
    <email>texar.pereyra@imss.gob.mx</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto Mexicano del Seguro Social</name>
      <address>
        <city>Leon</city>
        <state>Guanajuato</state>
        <zip>37320</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norma Amador, PhD</last_name>
      <phone>+52477174800</phone>
      <phone_ext>31315</phone_ext>
      <email>norma.amador@imss.gob.mx</email>
    </contact>
    <contact_backup>
      <last_name>Texar A Amador, MD</last_name>
      <phone>+524777174800</phone>
      <phone_ext>31742</phone_ext>
      <email>texar.pereyra@imss.gob.mx</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 22, 2014</lastchanged_date>
  <firstreceived_date>January 17, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Coordinación de Investigación en Salud, Mexico</investigator_affiliation>
    <investigator_full_name>Norma Amador Licona</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Seropositive HIV</keyword>
  <keyword>Omega 3 fatty acids</keyword>
  <keyword>Oxidative stress</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
